Angela C. Boroughs

Angela C. Boroughs

Auto-generated profile, based on publicly available information

Angela C. Boroughs

Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
ABAngela C. Boroughs
Angela C. Boroughs
RLRebecca C. Larson
Rebecca C. Larson
BCBryan D. Choi
Bryan D. Choi
ABAmanda A. Bouffard
Amanda A. Bouffard
LRLauren S. Riley
Lauren S. Riley
MMMarcela V. Maus
Marcela V. Maus
Tregs are key modulators of inflammation and are important for the maintenance of peripheral tolerance. Adoptive immunotherapy with polyclonal Tregs holds promise in organ transplantation, graft-versus-host disease, and autoimmune diseases but may be enhanced by antigen-specific, long-lived Tregs. We modified primary human Tregs with chimeric antigen receptors (CARs) bearing different costimulatory domains and performed in vitro analyses of their phenotype and function. While neither the presence of a CAR nor the type of costimulation domain influenced Foxp3 expression in Tregs, the costimulation domain of the CARs affected CAR-Treg surface phenotype and functions, such as cytokine production. Furthermore, signaling from the CD28 costimulation domain maintained CAR-Treg suppressor function, whereas 4-1B costimulation did not. In vivo, CAR-Tregs accumulated at sites expressing target antigen and suppressed antigen-specific effector T cell responses; however, only CAR-Tregs with CD28 signaling domains were potent inhibitors of effector T cell–mediated graft rejection in vivo. Our findings support the use of CD28-based CAR-Tregs for tissue-specific immune suppression in the clinic.

9 March 2018 in Science
Verified
Journal Article
Closed access
PDF file
VMVishnu Mohanan
Vishnu Mohanan
TNToru Nakata
Toru Nakata
ADA. Nicole Desch
A. Nicole Desch
CLChloé Lévesque
Chloé Lévesque
ABAngela Boroughs
Angela Boroughs
RXRamnik J. Xavier
Ramnik J. Xavier
Overcoming a barrier to IBD: Inflammatory bowel disease (IBD) is a group of disorders linked to inflammation of the gastrointestinal tract. Colitis is a type of IBD that affects the inner lining of the colon and has been linked to a gene known as C1orf106 . Mohanan et al. found that C1orf106 encodes a protein that stabilizes the integrity of epithelial junctions and enhances barrier defense (see the Perspective by Citi). IBD-associated mutations in C1orf106 lead to greater cytohesin-1 protein levels, changes in E-cadherin localization, and enhanced susceptibility to intestinal pathogens. Modulation of C1orf106 may thus hold promise for treating colitis and other IBDs. Science , this issue p. 1161 ; see also p. 1097